TIL vs. CGTX, CVM, DTIL, ELUT, ATRA, ENTX, JATT, GRTS, ATHA, and PLX
Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Cognition Therapeutics (CGTX), CEL-SCI (CVM), Precision BioSciences (DTIL), Elutia (ELUT), Atara Biotherapeutics (ATRA), Entera Bio (ENTX), JATT Acquisition (JATT), Gritstone bio (GRTS), Athira Pharma (ATHA), and Protalix BioTherapeutics (PLX). These companies are all part of the "biological products, except diagnostic" industry.
Instil Bio (NASDAQ:TIL) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Instil Bio received 86 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 53.33% of users gave Cognition Therapeutics an outperform vote while only 52.51% of users gave Instil Bio an outperform vote.
Cognition Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
Instil Bio has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.
60.6% of Instil Bio shares are held by institutional investors. Comparatively, 43.3% of Cognition Therapeutics shares are held by institutional investors. 54.7% of Instil Bio shares are held by company insiders. Comparatively, 23.8% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Instil Bio's return on equity of -51.27% beat Cognition Therapeutics' return on equity.
Instil Bio currently has a consensus price target of $25.00, suggesting a potential upside of 111.86%. Cognition Therapeutics has a consensus price target of $6.67, suggesting a potential upside of 243.64%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Instil Bio.
In the previous week, Instil Bio had 4 more articles in the media than Cognition Therapeutics. MarketBeat recorded 6 mentions for Instil Bio and 2 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.59 beat Instil Bio's score of -0.24 indicating that Cognition Therapeutics is being referred to more favorably in the news media.
Summary
Cognition Therapeutics beats Instil Bio on 8 of the 15 factors compared between the two stocks.
Get Instil Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Instil Bio Competitors List
Related Companies and Tools
